Clinical Guides
Approach to Neonatal Jaundice
A clinically focused approach to jaundice in the first 28 days, integrating age-in-hours bilirubin interpretation, haemolysis, sepsis, G6PD deficiency, cholestasis, feeding, phototherapy, exchange escalation and dependable follow-up in Indian newborn care.
MedNext Academy | 14 min read
Approach to Neonatal Jaundice
A clinically focused approach to jaundice in the first 28 days, integrating age-in-hours bilirubin interpretation, haemolysis, sepsis, G6PD deficiency, cholestasis, feeding, phototherapy, exchange escalation and dependable follow-up in Indian newborn care.
Summary
Neonatal jaundice is yellow discoloration caused by bilirubin accumulation during the first 28 days. It is common, but visual appearance cannot distinguish harmless transition from bilirubin concentrations capable of neurotoxicity or from serious underlying disease. Every assessment must anchor the bilirubin value to the baby's exact postnatal age in hours, gestational age and neurotoxicity risk factors. A number without its sampling time is unsafe. Jaundice in the first 24 hours, rapid progression, prematurity, suspected haemolysis, G6PD deficiency, sepsis, poor feeding or neurological change lowers the threshold for urgent evaluation.
The clinician separates predominantly unconjugated hyperbilirubinaemia from direct or conjugated hyperbilirubinaemia. Unconjugated bilirubin may rise from physiological transition, inadequate milk intake, haemolysis, bruising, polycythaemia, prematurity or impaired conjugation. Direct hyperbilirubinaemia is never explained as ordinary physiological jaundice; pale stools, dark urine, hepatomegaly or prolonged jaundice require an urgent cholestasis pathway. Bilirubin encephalopathy can begin with poor suck, altered tone, lethargy or irritability and progress to high-pitched cry, retrocollis, opisthotonus, apnoea or seizures.
Management is not based on skin colour or a fixed bilirubin cutoff. Use one validated, locally adopted hour-specific treatment chart, obtain serum confirmation when required, provide effective phototherapy above the appropriate threshold and escalate early when exchange transfusion may be needed. Continue feeding and lactation support while investigating the cause. Safe discharge requires a measured predischarge risk assessment, a named follow-up time and a route for urgent reassessment; reassurance without follow-up can miss the post-discharge peak.
How Common Is It?
Most newborns develop some visible or biochemical bilirubin elevation because bilirubin production is relatively high, hepatic uptake and conjugation are immature, and enterohepatic circulation is active. The 2022 American Academy of Pediatrics guideline states that more than 80% of newborn infants have some degree of jaundice. That estimate describes a broad newborn population and should not be presented as the incidence of severe hyperbilirubinaemia, kernicterus or treatment need. Most jaundice resolves without injury, while a small but clinically important group needs timely intervention.
Observed burden depends on gestational age, feeding support, timing of discharge, haemolytic disease prevention, G6PD prevalence, laboratory access and the treatment thresholds used. Studies that use different bilirubin nomograms or measure at different postnatal ages are not directly comparable. Hospital series overrepresent premature, unwell and referred babies. Community under-detection may be greater where skin pigmentation, poor lighting or early discharge makes visual recognition unreliable. Therefore this guide avoids inventing a single contemporary Indian prevalence.
The practical epidemiology is temporal. Unconjugated bilirubin commonly rises after birth and may peak after a baby has left the facility. Earlier onset is more concerning: visible jaundice during the first 24 hours requires urgent measurement and assessment. Persistence also changes the differential. In a term baby, jaundice continuing beyond about two weeks, or beyond about three weeks in a preterm baby under current guidelines definitions, prompts evaluation for prolonged jaundice, especially when stools are pale or urine stains the nappy dark. Local follow-up systems matter as much as population frequency.
Risk Factors
Risk factors for developing significant hyperbilirubinaemia include lower gestational age, jaundice within the first day, a bilirubin close to the treatment threshold before discharge, a rapid rate of rise, previous phototherapy, a sibling who required treatment, significant bruising or cephalohaematoma and suboptimal milk intake. Exclusive breastfeeding is not itself disease; risk arises when transfer is inadequate, feeds are infrequent or ineffective, weight loss is excessive, urine or stool output is poor, or maternal lactation support is unavailable. Delayed meconium passage and dehydration can increase enterohepatic circulation.
Haemolysis requires deliberate attention. Maternal red-cell antibodies, ABO or Rh incompatibility, a positive direct antiglobulin test in the correct context, hereditary spherocytosis and G6PD deficiency may accelerate bilirubin production. Ask about family history of neonatal jaundice, anaemia, splenectomy, gallstones or unexplained neonatal death and about ancestry linked to inherited red-cell disorders, without using race as a biological shortcut. G6PD-related haemolysis can be triggered by illness, fava exposure or oxidant medicines, yet severe jaundice may occur without an obvious trigger.
Neurotoxicity risk is not identical to risk of developing jaundice. Gestation below 38 weeks, isoimmune haemolytic disease, G6PD deficiency or other haemolysis, sepsis, clinical instability and low albumin in guideline-defined contexts can lower treatment thresholds. Premature infants below 35 weeks fall outside the AAP 2022 treatment graphs and require neonatal-unit protocols. Additional causes include polycythaemia, internal bleeding, sepsis, hypothyroidism, metabolic disease and impaired hepatic excretion. Risk assessment must be repeated when the baby becomes unwell or feeding changes.
Diagnosis
History
Record birth date and exact time, sampling time, gestational age and current age in completed hours. Ask when yellowing began and how it progressed, whether a sibling needed phototherapy, and whether maternal antibody screening or blood-group incompatibility was identified. Review delivery trauma, bruising, delayed cord or transfusion history, medicines and family history of haemolysis or G6PD deficiency. Take a precise feeding history: breast attachment, swallowing, feeds per 24 hours, supplements, weight change, wet nappies and stool transition. Fever, hypothermia, lethargy, irritability, vomiting, breathing difficulty and reduced feeding raise concern for sepsis. Dark urine, pale stools or prolonged jaundice suggest cholestasis.
Examination
Assess temperature, heart rate, breathing, perfusion, hydration, current weight and percentage change from birth. Examine jaundice in bright natural or white light at the sclera, gums and blanched skin, recognising that visual estimation is unreliable and changes may be harder to see in darker skin. Look for pallor, bruising, cephalohaematoma, petechiae, hepatosplenomegaly, dysmorphism, infection focus and signs of prematurity. Neurological assessment includes alertness, suck, cry and tone; hypotonia may precede hypertonia, retrocollis, opisthotonus, apnoea or seizures in acute bilirubin encephalopathy.
Investigations
Measure transcutaneous or total serum bilirubin according to age, gestation and local protocol; serum measurement is required when the transcutaneous value approaches a treatment threshold, is beyond the device range, or treatment is considered. Plot the total value on the selected hour-specific chart without subtracting direct bilirubin. For significant or rapidly rising jaundice, consider maternal and infant blood groups, DAT, haemoglobin or haematocrit, reticulocytes and smear. Test G6PD when indicated, remembering that testing during or soon after haemolysis can be falsely normal and may need repetition. If ill, investigate and treat sepsis urgently. Fractionate bilirubin for prolonged jaundice or cholestasis features; direct elevation requires liver, infectious, metabolic and anatomical evaluation rather than routine phototherapy alone.
Differential Diagnosis
Physiological jaundice is a diagnosis of pattern and exclusion: the baby is well, onset is after the first day, the trajectory fits gestation and age, feeding is adequate, and no haemolysis, infection or cholestasis clue is present. Suboptimal-intake hyperbilirubinaemia usually appears in the first week with ineffective milk transfer, excessive weight loss and reduced output. Breast-milk jaundice describes persistent unconjugated jaundice in a thriving breastfed infant after other causes have been considered; it must not be used to dismiss poor feeding or pale stools.
Increased bilirubin production follows ABO or Rh isoimmune haemolysis, G6PD deficiency, hereditary membrane disorders, bruising, cephalohaematoma, internal haemorrhage or polycythaemia. A rapidly rising bilirubin, anaemia, reticulocytosis, smear abnormality or family history supports this group, but individual tests are imperfect. Prematurity increases production and reduces clearance. Sepsis can produce unconjugated jaundice, cholestasis or both and may present with temperature instability, poor feeding, apnoea or nonspecific deterioration rather than fever.
Prolonged or direct hyperbilirubinaemia requires a different list: biliary atresia, neonatal hepatitis, sepsis or urinary infection, hypothyroidism, galactosaemia and other metabolic disease, alpha-1 antitrypsin deficiency and structural obstruction. Pale or chalky stools and dark urine are high-value clues. Jaundice with vomiting, poor weight gain, hepatomegaly, coagulopathy or hypoglycaemia is not a benign feeding variant. Congenital infection and endocrine disease may have additional examination signs. The differential should identify mechanisms that need immediate action—haemolysis, sepsis, neurotoxicity or biliary obstruction—before assigning a descriptive label.
Management
First determine whether the baby is clinically unstable or has acute bilirubin encephalopathy. Provide neonatal resuscitative support, check glucose, obtain urgent serum bilirubin and involve a unit capable of intensive phototherapy and exchange transfusion. If the bilirubin is at or near the exchange threshold, or neurological signs are present, escalate care while starting intensive phototherapy; do not wait for transfer arrangements to finish. Evaluate haemolysis and sepsis simultaneously. Exchange transfusion is a specialist intensive-care procedure with significant risks, blood-product requirements and continuous monitoring.
For a stable baby, select the treatment graph that matches gestational age and the presence or absence of neurotoxicity risk factors. Do not mix thresholds from current guidelines, AAP or a local chart within one episode. Phototherapy uses an artificial light source with appropriate wavelength, irradiance and exposed surface area. Verify equipment performance, protect the eyes according to device protocol, monitor temperature and hydration, and remeasure serum bilirubin at intervals determined by starting level, trajectory and risk. Sunlight is not a controllable substitute.
Feeding care is active treatment support. Observe a feed, correct positioning and attachment, encourage frequent effective feeding and use expressed maternal milk first when extra intake is clinically indicated and available. The decision to supplement follows hydration, weight, milk transfer and bilirubin trajectory, not a blanket rule. Treat proven infection and address haemolysis or other cause. Stop phototherapy and plan rebound testing using the adopted protocol and individual risk. Direct hyperbilirubinaemia requires urgent aetiological referral; lowering unconjugated bilirubin does not resolve cholestasis. Every plan includes follow-up after discharge.
Prescribing Information
Phototherapy is a dose-dependent treatment even though it is not a medicine: wavelength, measured irradiance, distance, exposed body surface, interruptions and equipment maintenance determine delivery. Write a clear order that identifies the indication, device or intensity, start time, monitoring schedule and escalation trigger. Monitor temperature, hydration and bilirubin response. A baby whose bilirubin continues to rise or fails to fall under verified intensive phototherapy needs reassessment for haemolysis, inadequate light delivery or another cause rather than simply more time.
Routine medicines do not replace phototherapy. Current guidelines describes intravenous immunoglobulin as an adjunct in selected Rh or ABO haemolytic disease with continued rapid bilirubin rise despite intensified phototherapy. The AAP 2022 technical review notes uncertain benefit and possible harm, so IVIG should be a neonatologist-led decision under the adopted protocol, not an automatic response to a positive DAT. Exchange transfusion requires compatible blood products, neonatal intensive care and specialist protocols. Albumin infusion, phenobarbitone and unproven traditional or homeopathic treatments should not be offered as general jaundice therapy.
Do not prescribe water or dextrose water to a breastfed baby as treatment for jaundice. Intravenous fluid is reserved for a clinical indication such as dehydration, inability to feed or escalation-level care. Antibiotics are used promptly when sepsis is suspected, following neonatal sepsis protocols and cultures where this does not delay treatment. Review maternal and neonatal medicines for haemolysis risk in G6PD deficiency. Any drug dose must be weight-, gestation- and organ-function specific; this guide deliberately does not provide a stand-alone prescription.
When to Refer
Jaundice visible in the first 24 hours requires urgent bilirubin measurement and medical assessment. Refer or transfer immediately for abnormal tone, poor suck, high-pitched cry, extreme sleepiness, irritability, arching, apnoea or seizures; a bilirubin at or approaching exchange level; a rapid rise suggesting haemolysis; or failure to respond to verified intensive phototherapy. A premature baby, clinically unstable newborn or infant below the gestational scope of the local chart needs neonatal-unit advice rather than extrapolation from a term chart.
Urgent paediatric assessment is also required for fever or hypothermia, respiratory difficulty, poor perfusion, recurrent vomiting, marked dehydration, excessive weight loss, reduced urine, failure to feed or a parent reporting that the baby is difficult to wake. Suspected isoimmune disease, G6PD deficiency or significant anaemia needs a pathway capable of serial bilirubin measurement and escalation. If same-day bilirubin testing is not locally available, transfer is safer than estimating severity by colour.
Refer prolonged jaundice for fractionated bilirubin and cause-directed evaluation, especially with pale stools, dark urine, hepatomegaly, bleeding, poor growth or illness. Direct hyperbilirubinaemia requires prompt specialist advice because delayed recognition of biliary obstruction can narrow treatment options. After routine discharge, follow-up timing is based on the measured bilirubin's distance below the hour-specific phototherapy threshold, gestation, feeding and support. State the exact date, time and location of review, who will measure bilirubin if needed, and what parents should do overnight if feeding or alertness worsens.
Red Flags
Neurological red flags for acute bilirubin encephalopathy include decreasing alertness, poor suck, hypotonia, a shrill or high-pitched cry and irritability, followed by hypertonia, retrocollis, opisthotonus, apnoea, fever or seizures. These signs are a medical emergency even if the last bilirubin result was below a threshold. Chronic bilirubin encephalopathy or kernicterus can cause permanent movement disorder, auditory neuropathy, gaze abnormality and dental enamel changes; prevention depends on recognising the earlier, reversible window.
Trajectory red flags are jaundice in the first day, a bilirubin rising unusually fast, a value close to exchange threshold, recurrence after phototherapy and a level inconsistent with the baby's apparent wellness. Haemolysis clues include pallor, anaemia, reticulocytosis, maternal antibodies, a positive DAT in context, family history or suspected G6PD deficiency. Sepsis clues include temperature instability, apnoea, respiratory distress, poor perfusion, lethargy and feeding failure. Prematurity and clinical instability increase vulnerability at lower bilirubin concentrations.
Cholestasis red flags are pale, white or chalky stools; dark urine that stains the nappy; hepatosplenomegaly; bleeding; poor weight gain; hypoglycaemia; or a raised direct bilirubin. Do not call these breast-milk jaundice. Feeding red flags are ineffective suck, few wet nappies, delayed stool transition and excessive weight loss. Systems red flags include discharge without a measured bilirubin risk assessment, inability to obtain timely repeat testing or no named follow-up. In those situations, change the care setting rather than asking the family to rely on visual observation.
Indian Clinical Context
India includes tertiary neonatal intensive care, district hospitals, private maternity units, health and wellness centres and home births with very different access to bilirubin measurement and exchange transfusion. The core safety principle is therefore planned linkage. A facility that can recognise jaundice but cannot measure serum bilirubin or deliver verified intensive phototherapy must know where and how to transfer a baby, including at night. Referral should occur before the exchange threshold is crossed, not after treatment failure. Transport must protect warmth, glucose, feeding and cardiorespiratory stability.
Visual assessment can under-recognise jaundice in darker skin and is unreliable at every skin tone. Teach families to look at sclera and gums in good light, but do not shift clinical responsibility onto parents. Before discharge, record gestational age, birth and discharge times, bilirubin value and time, feeding assessment, weight change, maternal blood group or antibodies where known, and the exact follow-up plan. Communication should use the family's language and explicitly mention poor feeding, reduced alertness, increasing yellowing, dark urine and pale stools.
G6PD deficiency and haemoglobin disorders vary by region and community; local prevalence can inform suspicion but not replace testing. Avoid known oxidant exposures when deficiency is confirmed or strongly suspected. Use the institution's validated treatment chart and consistent units, because copying a number from an international source without its gestational and hour-specific context is hazardous. AAP guidance applies to infants at least 35 weeks, while current guidelines uses a UK pathway for babies under 28 days; neither is an Indian national protocol. Local neonatal guidance and senior judgement govern care.
NMC Competency Mapping
The central NMC competency is PE19.15: describe the aetiology, clinical features and management of neonatal hyperbilirubinaemia. This guide expands that requirement into a safe sequence—recognition, exact age-in-hours interpretation, distinction between unconjugated and direct bilirubin, evaluation for haemolysis or sepsis, treatment thresholds, feeding support and follow-up. PE19.1 provides neonatal nomenclature and recognition of high-risk newborns, while PE19.3 addresses normal-neonate assessment, breastfeeding, follow-up and red flags.
Related competencies prevent a siloed answer. PE19.8 covers low birth weight and prematurity, which change bilirubin vulnerability and guideline scope. PE19.10 addresses neonatal hypoglycaemia, relevant in an unwell or poorly feeding baby. PE19.13 covers neonatal sepsis, an important cause and comorbidity. Physiology and pathology competencies on bilirubin metabolism and haemolytic anaemia supply mechanisms but do not replace bedside risk assessment. The curriculum assigns neonatal hyperbilirubinaemia at knowledge or know-how level; reading a guide does not certify independent phototherapy prescription, exchange transfusion or neonatal resuscitation.
A competent undergraduate should accurately calculate postnatal age, assess gestation, feeding, hydration and neurological state, recognise first-day jaundice and cholestasis, request appropriate bilirubin fractionation and haemolysis tests, and explain why thresholds depend on age and risk. The learner should communicate a follow-up plan and urgent warning signs to parents. Supervised nursery teaching should include plotting results on the locally approved chart, inspecting phototherapy equipment, observing feeding and understanding referral logistics. Procedural decisions remain with trained paediatric and neonatal teams.
Key Exam Pearls for NEET PG
Unconjugated bilirubin is lipid soluble and, when unbound exposure is sufficiently high in a vulnerable infant, can cross into the brain and cause acute bilirubin encephalopathy. Risk depends on more than total bilirubin: gestational age, haemolysis, sepsis, clinical instability and albumin-related binding matter. Always interpret total serum bilirubin by age in hours. Do not subtract direct bilirubin when using total-bilirubin treatment thresholds. Transcutaneous bilirubin is a screening measurement; serum confirmation is required near thresholds or when treatment is planned.
Jaundice in the first 24 hours is pathological until evaluated. A rapid rise suggests haemolysis. ABO incompatibility may affect a first pregnancy; Rh disease is linked to maternal alloimmunisation and prevention. G6PD testing can be falsely reassuring during acute haemolysis because older deficient red cells have been removed. Cephalohaematoma, bruising and polycythaemia increase bilirubin load. Suboptimal-intake jaundice is associated with poor transfer and weight loss, whereas breast-milk jaundice is considered in a thriving infant after exclusion of important disease.
Phototherapy converts bilirubin into more readily excreted photoisomers; effectiveness depends on irradiance and exposed surface area. Sunlight is not standard controlled treatment. Exchange transfusion is indicated by the adopted hour-specific threshold or acute encephalopathy and continues alongside intensive phototherapy during preparation. Direct hyperbilirubinaemia, pale stools and dark urine indicate cholestasis and demand urgent evaluation for biliary atresia and other causes. The highest-scoring answer combines bilirubin number, age, gestation, risk factors, feeding, cause and follow-up rather than quoting one memorised cutoff.
Frequently Asked Questions
Why must a neonatal bilirubin result include age in hours?
Bilirubin changes rapidly after birth, and treatment thresholds rise with postnatal age and differ by gestation and neurotoxicity risk. The same value may be below threshold in one baby and require escalation in another. Record birth time, sample time, gestational age and the exact chart used; a standalone bilirubin number is clinically incomplete.
Can breastfeeding continue while a jaundiced baby receives phototherapy?
Usually yes. Effective frequent feeding and lactation support are important, and brief breaks may be possible with standard phototherapy under the local protocol. Intensified treatment near exchange level may need uninterrupted exposure while enteral or intravenous support continues. Supplementation is based on milk transfer, hydration, weight and clinical risk, preferably using expressed maternal milk when available.
When should G6PD deficiency be suspected or retested?
Consider it with severe, rapidly rising or unexplained jaundice, haemolysis, relevant family history or ancestry, or poor response to phototherapy. A result obtained during or soon after a haemolytic episode can be falsely normal because younger circulating cells have higher enzyme activity. If suspicion remains, arrange repeat testing at an appropriate interval with specialist guidance.
Why are pale stools and dark urine urgent in a jaundiced newborn?
They suggest conjugated hyperbilirubinaemia and impaired bile flow rather than ordinary physiological jaundice. Biliary atresia, infection, endocrine or metabolic disease may be responsible, and delay can reduce treatment options. Fractionate bilirubin promptly and seek paediatric or hepatology advice; routine phototherapy does not treat the underlying cholestasis.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic